Gandhi V, Kantarjian H, Faderl S, et al. 2003. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res, 9:6335–42. Gandhi V, Plunkett W, Bonate PL, et al. 2006. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia:strategy for treat- ment. Clin Cancer Res, 12:4011–17. Gaynon PS. 2005. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol, 131:579–87. Gaynon PS, Harris RE, Altman AJ, et al. 2006. Bone marrow transplanta- tion versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy:Children’s Oncology Group study CCG-1941. J Clin Oncol, 24:3150–6. Gaynon PS, Qu RP, Chappell RJ, et al. 1998. Survival after relapse in childhood acute lymphoblastic leukemia:impact of site and time to ﬁrst relapse – the Children’s Cancer Group Experience. Cancer, 82:1387–95. Genini D, Adachi S, Chao Q, et al. 2000. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood, 96:3537–43. Gibson BE, Wheatley K, Hann IM, et al. 2005. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19:2130–8. Goulden N, Bader P, Van Der Velden V, et al. 2003. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol, 122:24–9. Grovas A, Fremgen A, Rauck A, et al. 1997. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer, 80:2321–32. Hijiya N, Franklin J, Rytting M, et al. 2007. A phase I study of clofarabine in combination with cyclophosphamide and etoposide:a new regimen in pediatric patients with relapsed or refractory acute leukemia. Proc Am Soc Clin Oncol, 26:abstract #9529. Hitchings GH, Elion GB, Falco EA, et al. 1950. Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci, 52:1318–35. Iqbal S, Lenz HJ. 2004. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol, 54(Suppl 1): S32–39. Jeha S, Gandhi V, Chan KW, et al. 2004. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103:784–9. Jeha S, Gaynon PS, Razzouk BI, et al. 2006a. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol, 24:1917–23. Jeha S, Kantarjian H. 2007. Clofarabine for the treatment of acute lympho- blastic leukemia. Expert Rev Anticancer Ther, 7:113–118. Jeha S, Razzouk B, Gaynon P, et al. 2006b. Clofarabine in children with refractory/relapsed acute leukemia: results of 2 phase ii open label studies. ASH Annual Meeting Abstracts, 108:4460. Jemal A, Tiwari RC, Murray T, et al. 2004. Cancer statistics, 2004. CA Cancer J Clin, 54:8–29. Kantarjian H, Gandhi V, Cortes J, et al. 2003a. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 102:2379–86. Kantarjian HM, Gandhi V, Kozuch P, et al. 2003b. Phase I clinical and pharmacology study of clofarabine in patients with solid and hemato- logic cancers. J Clin Oncol, 21:1167–73. Kantarjian H, Jeha S, Gandhi V, et al. 2007. Clofarabine:Past, present, and future. Leuk Lymphoma, Aug 13:1–9 [epub ahead of print]. Kearns P, Michel G, Nelken B, et al. 2006. BIOV-111a European phase II trial of clofarabine (Evoltra) in refractroy and relapsed childhood acute lymphoblastic leukemia. Blood, 108:527a (abstract #1859). Knechtli CJ, Goulden NJ, Hancock JP, et al. 1998. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92:4072–9. Therapeutics and Clinical Risk Management 2008:4(2) Clofarabine in pediatric leukemias Kurtzberg J. 2007. The long and winding road of the clinical development of Nelarabine. Leuk Lymphoma, 48:1–2. Levis M, Smith BD, Beran M, et al. 2005. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts, 106:403. Miser JS, Kinsella TJ, Triche TJ, et al. 1987. Ifosfamide with mesna uroprotection and etoposide:an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol, 5:1191–8. Nguyen K, Cheng S-C, Raetz E, et al. 2006. Factors inﬂuencing survival after relapse from childhood ALL: A Children’s Oncology Group study. ASH Annual Meeting Abstracts, 108:1855. Parker WB, Shaddix SC, Chang CH, et al. 1991. Effects of 2-chloro-9- (2-deoxy-2-ﬂuoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5’-triphosphate. Cancer Res, 51:2386–94. Parker WB, Shaddix SC, Rose LM, et al. 1999. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- ﬂuoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-ﬂuoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-diﬂuoro- beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol, 55:515–20. Plunkett W, Gandhi V. 2001. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif, 19:21–45. Pollard JA, Alonzo TA, Gerbing RB, et al. 2006. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood, 108:2764–9. Powell BL, Moser B, Stock W, et al. 2006. Preliminary results from the North American Acute Promyelocytic Leukemia (APL) study C9710. ASH Annual Meeting Abstracts, 108:566. Powell B, Moser B, Stock W, et al. 2007. Effect of consolidation with arsenic trioxide (As 2 O 3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL):North American Intergroup Protocol C9710. Proc Am Soc Clin Oncol, 26:2. Pui, C.H, Jeha, S. 2005b. Clofarabine. Nat Rev Drug Discov, (Suppl): S12–13. Pui CH, Jeha S, Kirkpatrick P. 2005a. Clofarabine. Nat Rev Drug Discov, 4:369–70. Raetz EA, Borowitz MJ, Devidas M, et al. 2006. Outcomes of children with ﬁrst marrow relapse: Results from Children’s Oncology Group (COG) study AALL01P2. ASH Annual Meeting Abstracts, 108:1871. Reinhardt D, Diekamp S, Fleischhack G, et al. 2004. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie, 27:269–72. Schein PS. 2001. The case for a new national program for the development of cancer therapeutics. J Clin Oncol, 19:3142–53. Schultz KR, Pullen DJ, Sather HN, et al. 2007. Risk- and response-based classi- ﬁcation of childhood B-precursor acute lymphoblastic leukemia:a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood, 109:926–35. Sievers EL, Larson RA, Stadtmauer EA, et al. 2001. Efﬁcacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in ﬁrst relapse. J Clin Oncol, 19:3244–54. Skipper HE, Thomson JR, Elion GB. et al. 1954. Observations on the anti- cancer activity of 6-mercaptopurine. Cancer Res, 14:294–8. Tallman MS. 2006. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol, 19:311–20. Webb DK. 1999. Management of relapsed acute myeloid leukaemia. Br J Haematol, 106:851–9. Wells RJ, Adams MT, Alonzo TA, et al. 2003. Mitoxantrone and cytara- bine induction, high-dose cytarabine, and etoposide intensiﬁcation for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951. J Clin Oncol, 21:2940–7. Xie C, Plunkett W. 1995. Metabolism and actions of 2-chloro-9-(2-deoxy- 2-ﬂuoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res, 55:2847–52. 335